广东泰恩康医药股份有限公司 2026 年员工持股计划（草案）摘要 证券简称：泰恩康 证券代码：301263 广东泰恩康医药股份有限公司 2026 年员工持股计划 （草案）摘要 二〇二六年一月 1 广东泰恩康医药股份有限公司 2026 年员工持股计划（草案）摘要 声明 本公司及董事会全体成员保证本员工持股计划及其摘要内容的真实、准确和 完整，没有虚假记载、误导性陈述或重大遗漏。 2 广东泰恩康医药股份有限公司 2026 年员工持股计划（草案）摘要 风险提示 一、广东泰恩康医药股份有限公司（以下简称"泰恩康""公司"或"本公 司"）2026 年员工持股计划（草案）（以下简称"本员工持股计划草案"）须 经公司股东会批准后方可实施，本员工持股计划草案能否获得公司股东会批准， 存在不确定性。 二、有关公司 2026 年员工持股计划（以下简称"本员工持股计划"）的具 体的资金来源、出资金额、预计规模和具体实施方案等属初步结果，能否完成实 施，存在不确定性。 三、若员工认购份额不足，本员工持股计划存在低于预计规模的可能性。 四、股票价格受公司经营业绩、宏观经济周期、国际/国内政治经济形势及 投资者心理等多种复杂因素影响。因 ...

证券代码：301263 证券简称：泰恩康 公告编号：2026-007 广东泰恩康医药股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 重要提示： 根据《中华人民共和国公司法》及《广东泰恩康医药股份有限公司章程》（以 下简称"《公司章程》"）的规定，广东泰恩康医药股份有限公司（以下简称"公 司"）于 2026 年 1 月 28 日召开第五届董事会第十三次会议审议通过《关于召开 公司 2026 年第一次临时股东会的议案》，公司决定于 2026 年 2 月 13 日（星期五） 召开 2026 年第一次临时股东会。现将本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》 的有关规定。 4、会议时间： （1）现场会议时间：2026 ...

证券代码：301263 证券简称：泰恩康 公告编号：2026-008 广东泰恩康医药股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向下降 50%以上情形 （1）以区间数进行业绩预告的 | 项目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东 | 盈利：2,500 | 万元-3,500 | 万元 | 盈利：10,822.00 | 万 | | 的净利润 | 比上年同期下降：67.66%-76.90% | | | 元 | | | 扣除非经常性损益后 | 盈利：2,700 | 万元-3,700 | 万元 | 盈利：10,604.51 | 万 | | 的净利润 | 比上年同期下降：65.11%-74.54% | | | 元 | | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务 ...

证券代码：301263 证券简称：泰恩康 公告编号：2026-005 广东泰恩康医药股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 广东泰恩康医药股份有限公司（以下简称"公司"）第五届董事会第十三 次会议（以下简称"会议"）通知于 2026 年 1 月 25 日以书面送达或电子邮件 方式向全体董事发出，会议于 2026 年 1 月 28 日以通讯会议的方式召开。会议 由董事长郑汉杰先生召集主持，应出席董事 7 人，实际出席董事 7 人，全部高 级管理人员列席会议。 本次董事会会议召集、召开符合《中华人民共和国公司法》（以下简称 "《公司法》"）《广东泰恩康医药股份有限公司章程》（以下简称"《公司 章程》"）等的规定，会议决议合法、有效。 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议通过议案如下： （一）审议通过《关于<广东泰恩康医药股份有限公司 2026 年员工持股计 划（草案）>及其摘要的议案》 为了建立和完善劳动者与所有者的利益共享机制，进一步改善公司治理水 平，提高职工的凝 ...

广东泰恩康医药股份有限公司 董事会薪酬与考核委员会关于公司 2026 年员工持股计划 相关事项的核查意见 广东泰恩康医药股份有限公司（以下简称"公司"）董事会薪酬与考核委员会 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证 券法》（以下简称"《证券法》"）《关于上市公司实施员工持股计划试点的指导 意见》（以下简称"《指导意见》"）《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"《自律监管指引第 2 号》"）等 法律、法规、规章和规范性文件，以及《广东泰恩康医药股份有限公司章程》（以 下简称"《公司章程》"）的规定，对公司 2026 年员工持股计划（以下简称"本员 工持股计划"）相关事项进行了核查，并发表核查意见如下： 一、公司不存在《指导意见》《自律监管指引第 2 号》等法律、法规、规章 和规范性文件所禁止实施员工持股计划的情形。 三、公司审议本员工持股计划相关议案的决策程序合法、有效。本员工持股 计划遵循公司自主决定、员工自愿参加的原则，公司实施本员工持股计划前，通 过职工代表大会等方式，充分征求员工意见，不存在摊派、强行分配等方式强制 员工参 ...

Core Viewpoint - The announcement by TianKang (301263) highlights the approval of a clinical trial for CKBA cream, aimed at treating non-segmental vitiligo in children aged 2-12, marking a significant step in addressing an unmet medical need in this demographic [1] Group 1: Clinical Trial Approval - TianKang's subsidiary, Jiangsu Bochuangyuan Biopharmaceutical Technology Co., Ltd., received a clinical trial approval notice from the National Medical Products Administration for CKBA cream [1] - The trial will assess the safety, efficacy, and pharmacokinetic characteristics of CKBA cream in combination with narrowband ultraviolet B (NB-UVB) therapy [1] Group 2: Market Opportunity - CKBA cream is an innovative drug developed by the company specifically for treating pediatric vitiligo [1] - Approximately 32%-40% of total vitiligo patients are children, and currently, there are no approved products available for this indication globally [1]

Group 1 - Huibo Yuntong plans to acquire 65.47% of Baode Computer System shares through a share issuance and has received acceptance from the Shenzhen Stock Exchange for its application [1] - Mingyang Smart Energy intends to purchase 100% of Dehua Chip's equity through a combination of share issuance and cash payment, with stock resuming trading on January 23, 2026 [2] - Sanhua Intelligent Control's controlling shareholder and board members plan to reduce their holdings by up to 0.2425% of the company's shares [3] Group 2 - Wuchan Jinlun's shareholder plans to reduce holdings by up to 3% of the company's total shares [4] - Chengdu Road and Bridge expects a net loss of 65 million to 97.5 million yuan for 2025, compared to a loss of 92.17 million yuan in the previous year [5] - Guoxin Technology anticipates a net loss of 238 million yuan for 2025, an increase in loss of 56.97 million yuan compared to the previous year [6] Group 3 - Taiankang's subsidiary received approval for a clinical trial of CKBA ointment for treating vitiligo in children aged 2-12 [7] - Boyun New Materials' shareholder plans to reduce holdings by up to 1% of the company's total shares [8] - *ST Shengwu has terminated its major asset restructuring plan and expects a net profit of 28.5 million to 32.5 million yuan for 2025, compared to a loss of 19.84 million yuan in the previous year [9] Group 4 - Junchen Technology's shareholder plans to reduce holdings by up to 2.94% of the company's shares [10] - Haiguang Information's shareholder plans to reduce holdings by up to 0.5% of the company's shares [11] - ST Juewei expects a net loss of 160 million to 220 million yuan for 2025, compared to a profit of 227 million yuan in the previous year [12] Group 5 - Nanjing Bank reported total assets exceeding 3 trillion yuan by the end of 2025, with a revenue of 55.54 billion yuan, up 10.48% year-on-year [13] - Haitan Ruisheng's shareholders plan to reduce holdings by up to 5% of the company's shares [14] - Zhaoyi Innovation expects a net profit of approximately 1.61 billion yuan for 2025, a year-on-year increase of about 46% [15] Group 6 - Xiangrikui is discussing a repayment arrangement for a deposit of 40 million yuan with Shanghai Xipu Technology [16] - Yinglian Co. signed a strategic agreement with LG Chem to develop new polymer materials for lithium battery applications [17] - Yingfang Micro expects a net loss of 69 million to 97 million yuan for 2025, compared to a loss of 61.97 million yuan in the previous year [18] Group 7 - Heshun Electric's shareholders plan to reduce holdings by up to 3.5% of the company's shares [20] - Guanghua Technology expects a net profit of 85 million to 120 million yuan for 2025, reversing a loss of 205 million yuan in the previous year [21] - Ruichuang Weina anticipates a net profit of approximately 1.1 billion yuan for 2025, a year-on-year increase of about 93% [22] Group 8 - Huatu Mountain Ding's shareholder plans to reduce holdings by up to 3% of the company's shares [23] - Yinfeng Storage's subsidiary won two procurement projects with a total value of approximately 1.23 billion yuan [24] - Hengyi Petrochemical plans to repurchase shares worth 500 million to 1 billion yuan for employee stock ownership plans [25] Group 9 - Mengcao Ecology's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [26] - Tefa Service's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Green Alliance Technology's shareholders plan to reduce holdings by up to 4% of the company's shares [28] Group 10 - Yunyi Electric plans to repurchase shares worth 100 million to 150 million yuan for employee stock ownership plans [29] - Dongpeng Beverage plans to invest 1.1 billion yuan in a new production base in Chengdu [30] - Zhongyuan Co. expects a net profit of 139 million to 158 million yuan for 2025, a year-on-year increase of 80% to 105% [31] Group 11 - Qiangyi Co. expects a net profit of 368 million to 399 million yuan for 2025, a year-on-year increase of 57.87% to 71.17% [32] - Guochuang High-tech anticipates a net profit of 16 million to 24 million yuan for 2025, reversing a loss of 49.1 million yuan in the previous year [33] - Yuandong Bio received a drug registration certificate for a pediatric medication [34] Group 12 - Liya Technology expects a net profit of 300 million to 380 million yuan for 2025, reversing a loss of 889 million yuan in the previous year [35] - Dongfeng Co. anticipates a net loss of 390 million to 480 million yuan for 2025, compared to a profit of 29.16 million yuan in the previous year [36] - Huaming Equipment reported a 15.29% year-on-year increase in net profit for 2025 [37] Group 13 - Botong Integrated expects a net profit of 17.19 million to 25.78 million yuan for 2025, reversing a loss from the previous year [38] - Qingsong Co. anticipates a net profit of 130 million to 165 million yuan for 2025, a year-on-year increase of 137.73% to 201.74% [39] - Ruihua Tai's shareholder plans to reduce holdings by up to 3% of the company's shares [41]

Group 1 - The core point of the news is that Taiankang's stock experienced a decline of 2.09% on January 22, with a trading volume of 150 million yuan, indicating a potential concern in market sentiment [1] - On January 22, Taiankang had a financing buy-in amount of 22.96 million yuan and a net financing buy of 6.63 million yuan, with a total financing and securities balance of 976 million yuan, which is high compared to historical levels [1] - The company’s financing balance of 974 million yuan accounts for 7.19% of its circulating market value, exceeding the 80th percentile of the past year, indicating a high level of leverage [1] Group 2 - As of September 30, Taiankang had 12,000 shareholders, an increase of 9.32% from the previous period, while the average circulating shares per person decreased by 8.53% to 25,381 shares [2] - For the period from January to September 2025, Taiankang reported a revenue of 526 million yuan, a year-on-year decrease of 8.13%, and a net profit attributable to shareholders of 31.41 million yuan, down 73% year-on-year [2] - Since its A-share listing, Taiankang has distributed a total of 460 million yuan in dividends, with 377 million yuan distributed over the past three years [2]

Group 1 - The core point of the news is that Guangdong Taiankang Pharmaceutical Co., Ltd. has received approval for a Phase II clinical trial of CKBA cream for treating non-segmental vitiligo in children aged 2 to 12, marking a significant advancement in innovative treatments for pediatric vitiligo [1] - The clinical trial approval was granted by the National Medical Products Administration, allowing the company to conduct a multi-center, randomized, double-blind, placebo-controlled study to assess safety, efficacy, and pharmacokinetics [1] - Vitiligo is a chronic autoimmune disease affecting 0.5% to 2.0% of the global population, with children representing approximately 32% to 40% of total patients, highlighting a significant unmet clinical need for treatments specifically for this demographic [1] Group 2 - CKBA is a first-in-class immunomodulator targeting ACC1/MFE-2, which suppresses the differentiation of CD8+ T cells and downregulates the expression of IFN-γ and IL-17, thereby improving the immune environment of the skin and preventing the expansion of vitiligo [2] - The NB-UVB therapy activates melanocyte stem cells, promoting their differentiation into mature melanocytes to produce melanin, complementing the action of CKBA [2] - CKBA is derived from natural products and has been recognized for its innovative value and clinical potential, holding intellectual property rights in China, the United States, the European Union, and Japan [2]

Core Viewpoint - The company Tianenkang (301263) announced that its subsidiary, Bochuangyuan, has received approval from the National Medical Products Administration for a clinical trial of CKBA cream in children aged 2 to 12 with non-segmental vitiligo [1] Group 1 - The clinical trial is a multi-center, randomized, double-blind, placebo-controlled Phase II study [1] - The study will evaluate the safety, efficacy, and pharmacokinetic characteristics of CKBA cream combined with narrowband ultraviolet B (NB-UVB) therapy [1] - The trial specifically targets participants who are children aged 2 years and older [1]